No OS Improvement with CDK4/6 Inhibitors Used in First- Compared with Second-Line Treatment in Patients with HR-positive, HER2-negative ABC By Ogkologos - March 3, 2026 279 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the SONIA study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR New Technology System Allows Patients To Get A Mammogram And Biopsy... June 30, 2020 Mother and Son with Shared BRCA Gene Mutation Go Through Cancer... September 23, 2020 Molecular Analysis for Precision Oncology Congress 2022, 14-16 October 2022, Amsterdam,... September 29, 2022 Liquid Biopsies on the Horizon for Children with Solid Cancers April 11, 2023 Load more HOT NEWS Five Fraction SBRT Noninferior to Moderately Fractionated Image-Guided Radiotherapy for Patients... FDA Grants Regular Approval to Enfortumab Vedotin-ejfv for Locally Advanced or... Use of Immune Checkpoint Inhibitors is Safe and Effective in Patients... AI and remote monitoring are shaping a new patient journey in...
